Semaglutide: a new drug for the treatment of obesity.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0112037 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-5248 (Electronic) Linking ISSN: 00126543 NLM ISO Abbreviation: Drug Ther Bull Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2007- : London : BMJ Pub. Group
      Original Publication: London, Consumers' Association
    • Subject Terms:
      Diabetes Mellitus, Type 2*/drug therapy; Humans ; Hypoglycemic Agents/adverse effects ; Glucagon-Like Peptides/adverse effects ; Obesity/drug therapy
    • Abstract:
      Semaglutide (▼Ozempic solution for injection, ▼Rybelsus tablets-Novo Nordisk) was initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In 2021 and 2022, regulatory agencies in the USA and Europe licensed semaglutide (▼Wegovy solution for injection-Novo Nordisk) for the treatment of individuals who are obese, or overweight and who have at least one weight-related comorbidity. Manufacturer-sponsored randomised controlled trials have shown a loss of almost 12% of body weight over a 68-week period, however, once the medication is stopped people regain most of their pretreatment weight. Gastrointestinal adverse events occur commonly with semaglutide, and pancreatitis, diabetic retinopathy and severe allergic reactions have also been reported. Extensive hype in social and general media has resulted in increased demand for semaglutide leading to supply problems across the various licensed products including those used for treatment of diabetes. In the UK, the National Institute for Health and Care Excellence has recommended semaglutide as an option for weight management for a maximum treatment duration of 2 years. Further studies are underway to assess the effect of semaglutide on longer-term health benefits.
      Competing Interests: Competing interests: None declared. Refer to the online supplementary files to view the ICMJE form(s).
      (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
    • Contributed Indexing:
      Keywords: Drug-Related Side Effects and Adverse Reactions; Obesity
    • Accession Number:
      0 (Hypoglycemic Agents)
      53AXN4NNHX (semaglutide)
      62340-29-8 (Glucagon-Like Peptides)
    • Publication Date:
      Date Created: 20231025 Date Completed: 20231201 Latest Revision: 20231201
    • Publication Date:
      20231201
    • Accession Number:
      10.1136/dtb.2023.000007
    • Accession Number:
      37879878